Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Endologix, Inc. (ELGX): Deerfield Management Upping its Game

It seems the recent decline in Endologix, Inc. (NASDAQ:ELGX)’s stock by around 20% has made it more lucrative for hedge funds. As a recent filing with Securities and Exchange Commission (SEC) shows, James E. Flynn’s Deerfield Management has increased its stake in the company to over 4.48 million shares from over 1.48million shares that it owned previously. Deerfield now owns a total of 6.7% stake in the company as a passive investor.

Endologix, Inc. (NASDAQ:ELGX)

Deerfield Management is life sciences-focused hedge fund that invests in both publicly traded and private companies. From its humble beginnings in 1994 with $17 million in assets under management, it has now grown to managing over $5 billion. Deerfield invests in companies across the healthcare spectrum from early state drug research start-ups to mature healthcare services and device companies. In the second quarter of 2014, the fund increased its stake significantly in Allergan, Inc. (NYSE:AGN), shares of which are up more than 45% in the last 6 months, and Keryx Biopharmaceuticals (NASDAQ:KERX), which is up more than 10% in last six months and more than 70% year over year. Most of the large holdings of Deerfield have outperformed the market significantly in the last one year, generating returns in excess of 50%.

Apart from Deerfield, Justin John Ferayorni’s Tamarack Capital Management is also bullish on Endologix, Inc. (NASDAQ:ELGX). In the second quarter of 2014, it increased its stake in the company by 67% to 2.38 million shares. Endologix, Inc. (NASDAQ:ELGX) also features as a prominent pick of Donald Chiboucis’ Columbus Circle Investors, which as of June 30, 2014 owns 1.35 million shares.

Endologix, Inc. (NASDAQ:ELGX) is a $760 million market cap company that manufactures minimally invasive treatments for aortic disorders. The company expects global revenues for the fiscal year 2014 of in the range of $145 million to $148 million, which represents a growth of  10% to 12% over the revenues it reported for 2013. It also expects the net loss per share to be in the range of $0.37 to $0.43. Most analysts and brokerages are positive on the stock with average recommendation being ‘Overweight’ and average target price amounting to $15.17 per share.

Deerfield Management is life sciences focused fund, which means it watches closely any development in that sector and bets its money only when it is thoroughly convinced. A hedge fund with $5 billion in management has several resources, which an average investor doesn’t. However, an average investor can make similar returns, if they track the activity of these funds and emulate their strategies.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.